We are live on ! Find out more
GILD icon

Gilead Sciences

1,326 hedge funds and large institutions have $139B invested in Gilead Sciences in 2014 Q3 according to their latest regulatory filings, with 126 funds opening new positions, 465 increasing their positions, 615 reducing their positions, and 51 closing their positions.

New
Increased
Maintained
Reduced
Closed

147% more first-time investments, than exits

New positions opened: 126 | Existing positions closed: 51

46% more funds holding in top 10

Funds holding in top 10: 164240 (+76)

20% more capital invested

Capital invested by funds: $116B → $139B (+$22.7B)

5% more funds holding

Funds holding: 1,2621,326 (+64)

24% less repeat investments, than reductions

Existing positions increased: 465 | Existing positions reduced: 615

36% less call options, than puts

Call options by funds: $2.53B | Put options by funds: $3.96B

Holders
1,326
Holders Change
+64
Holders Change %
+5.07%
% of All Funds
38.47%
Holding in Top 10
240
Holding in Top 10 Change
+76
Holding in Top 10 Change %
+46.34%
% of All Funds
6.96%
New
126
Increased
465
Reduced
615
Closed
51
Calls
$2.53B
Puts
$3.96B
Net Calls
-$1.43B
Net Calls Change
-$802M
Name Holding Trade Value Shares
Change
Change in
Stake
NIM
351
Nexus Investment Management
Ontario, Canada
$21M -$203K -2,075 -1%
BA
352
Boston Advisors
Massachusetts
$21M +$37.2K +380 +0.2%
ABI
353
Adamant Biomedical Investments
Switzerland
$20.9M +$19.2M +196,390 New
FLPIM
354
F.L. Putnam Investment Management
Massachusetts
$20.5M -$271K -2,765 -1%
JCM
355
Janney Capital Management
Pennsylvania
$20.5M +$18.5M +189,408 +6,059%
AIA
356
Avalon Investment & Advisory
Texas
$20.2M +$534K +5,453 +3%
Truist Financial
357
Truist Financial
North Carolina
$20.1M -$1.35M -13,789 -7%
MOACM
358
Mutual of America Capital Management
New York
$20.1M -$516K -5,271 -3%
JCM
359
Jag Capital Management
Missouri
$20M -$1.74M -17,745 -9%
ST
360
Spot Trading
Illinois
$19.9M +$14.8M +151,018 +415%
AR
361
Advisory Research
Illinois
$19.9M +$18M +184,192 +7,580%
DBG
362
De Burlo Group
Massachusetts
$19.8M -$1.35M -13,800 -7%
CIA
363
CCM Investment Advisers
South Carolina
$19.8M -$584K -5,966 -3%
SIA
364
Sit Investment Associates
Minnesota
$19.3M -$112K -1,140 -0.6%
HighTower Advisors
365
HighTower Advisors
Illinois
$19.1M -$1.13M -11,550 -6%
BAM
366
Barrett Asset Management
New York
$19.1M +$267K +2,725 +2%
PI
367
PineBridge Investments
New York
$19.1M +$1.57M +16,041 +10%
PTC
368
Philadelphia Trust Company
Pennsylvania
$19.1M -$2.58M -26,378 -13%
BIA
369
Biondo Investment Advisors
Pennsylvania
$19.1M +$660K +6,737 +4%
FLII
370
First Long Island Investors
New York
$18.8M +$732K +7,475 +4%
BKBG
371
BHF Kleinwort Benson Group
Belgium
$18.7M -$228K -2,325 -1%
BAM
372
Baring Asset Management
United Kingdom
$18.7M +$17.2M +175,206 New
CW
373
Cabot-Wellington
Massachusetts
$18.6M -$549K -5,610 -3%
LI
374
LMCG Investments
Massachusetts
$18.5M -$887K -9,054 -5%
BVDMP
375
Bedrijfstakpensioenfonds Voor De Media PNO
Netherlands
$18.4M +$4.9M +50,000 +41%

GILD Hedge Fund Activity: Q3 2014 in Review

1,326 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q3 2014, worth a combined $139B — up 20% from $116B a quarter earlier.

Buyers outnumbered sellers: 126 funds opened new GILD positions and 51 closed out — a net gain of 75 holders — while 465 added to existing stakes and 615 trimmed.

The largest buyer was BNP Paribas Financial Markets, adding an estimated $226M. The largest seller was Capital Research Global Investors, cutting an estimated $1.52B.

  • 1,326 institutional investors held Gilead Sciences (GILD) as of Q3 2014, up from 1,262 in Q2 2014.
  • Funds reported $139B of Gilead Sciences stock for Q3 2014, up 20% quarter-over-quarter.
  • 126 funds opened new Gilead Sciences positions in Q3 2014 and 51 closed out, a net change of +75 holders.
  • The largest Gilead Sciences buyer in Q3 2014 was BNP Paribas Financial Markets, an estimated $226M added.
  • The largest Gilead Sciences seller in Q3 2014 was Capital Research Global Investors, an estimated $1.52B sold.

Based on aggregated 13F filings for Q3 2014.